Inevitable Cancer Development Linked to Pfizer and Moderna COVID Vaccines Can Be Combated with Ivermectin
In recent times, there has been a growing debate surrounding the use of ivermectin, an antiparasitic drug, as a potential cancer treatment. While preclinical studies have shown some promising anticancer effects, it is crucial to distinguish between these laboratory findings and the real-world application in humans.
Ivermectin has demonstrated the ability to inhibit tumor growth in a breast cancer mouse model at a human dose of two mg/kg. However, it is essential to note that these findings are primarily from preclinical studies and not from robust, large-scale clinical trials in humans. The clinical use of ivermectin for cancer remains experimental, with no approved guidelines and a lack of Phase 1/2/3 trials.
Contrary to some claims, there is currently no credible scientific evidence supporting the use of ivermectin as a cancer treatment specifically for chemotherapy-resistant tumors caused by COVID-19 mRNA vaccines. The premise that chemotherapy-resistant tumors are caused by COVID-19 mRNA vaccines has no scientific support in current medical literature or authorized clinical research.
The U.S. Food and Drug Administration (FDA) has taken a stance on this matter, agreeing to permanently take down its social media posts urging people to avoid using ivermectin for COVID-19. A lawsuit was filed against the FDA by doctors Paul Marik, Mary Talley Bowden, and Robert Apter, alleging that the FDA is meddling with their capacity to practice medicine. However, the lawsuit was initially dismissed based on the FDA's "sovereign immunity."
It is important to emphasize that ivermectin, while showing potential in certain cancer cell lines, is not a substitute for evidence-based cancer treatments like chemotherapy. Healthcare experts caution against using ivermectin as a cancer therapy outside of approved clinical trials and warn against misinformation that may lead patients to forgo proven treatments.
In terms of the drug's sensitivity across various cancer cell lines, the most sensitive are ovarian, breast, glioblastoma (brain), lung, colon, uterine squamous cell carcinoma (SCC), hepatocellular, triple-negative breast cancer (TNBC), pancreatic, and endometrial. On the other hand, osteosarcoma, gastric, and melanoma cell lines are the least sensitive to ivermectin.
The debate surrounding ivermectin's use in cancer treatment is complex and ongoing. As more research is conducted, it is hoped that a clearer understanding of the drug's potential role in cancer therapy will emerge. However, it is crucial that any decisions regarding treatment are made in consultation with healthcare providers and based on the best available evidence.
References: 1. Natural News 2. Makismd.substack.com 3. HindustanTimes.com 4. Robert F. Kennedy Jr tweet 5. Dr. Mary Talley Bowden's Twitter comment 6. U.S. Court of Appeals for the Fifth Circuit ruling 7. Australian politician Craig Kelly's statement 8. FDA's removal of posts
